Ravi, V., Brohl, A. S., Chawla, S. P., Attia, S., Riedel, R. F., Liebner, D. A., … Maki, R. G. (2018). TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma. In Journal of Clinical Oncology (Vol. 36, pp. TPS11590–TPS11590). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.tps11590

Ravi, Vinod, Andrew Scott Brohl, Sant P. Chawla, Steven Attia, Richard F. Riedel, David A. Liebner, Katherine Anne Thornton, et al. “TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.” In Journal of Clinical Oncology, 36:TPS11590–TPS11590. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.tps11590.

Ravi V, Brohl AS, Chawla SP, Attia S, Riedel RF, Liebner DA, et al. TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS11590–TPS11590.

Ravi, Vinod, et al. “TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. TPS11590–TPS11590. Crossref, doi:10.1200/jco.2018.36.15_suppl.tps11590.

Ravi V, Brohl AS, Chawla SP, Attia S, Riedel RF, Liebner DA, Thornton KA, Basu Mallick A, Mehta CR, Liu L, Alvarez D, Theuer CP, Robinson SI, Penel N, Stacchiotti S, Tap WD, Jones RL, Maki RG. TAPPAS: An adaptive enrichment phase 3 trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. TPS11590–TPS11590.